Skip to main content

Grafa News and Videos — Page 264

Grafa Headlines

Grafa
Health

Summit Therapeutics highlights ivonescimab Phase III biliary tract cancer data

Summit Therapeutics (NASDAQ:SMMT) announced that data from the Phase III HARMONi-GI1 trial evaluating ivonescimab, a potential first-in-class investigational bispecific antibody, will be presented at the Presidential Symposium II during the European Society for Medical Oncology (ESMO) 2026 Congress.

Read more: Summit Therapeutics highlights ivonescimab Phase III biliary tract cancer data

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift